Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Tipo de documento
Ano de publicação
Intervalo de ano de publicação
1.
Ter Arkh ; 93(7): 805-810, 2021 Jul 23.
Artigo em Russo | MEDLINE | ID: mdl-36286732

RESUMO

Indications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with primary myelofibrosis are intermediate-2 and high-risk group of DIPSS (Dynamic International Prognostic Scoring System), beginning of the disease in childhood. The other adverse factors affect engraftment and survival after allo-HSCT, example partialy matched donor. But the result of allo-HSCT from matched related donors and result of allo-HSCT from haploidentical donors are comparable. The method for haploidentical hematopoietic stem cell transplantation is T-cell-depletion. This is clinical case of T-cell-depleted haploidentical hematopoietic stem cell transplantation in patient with primary myelofibrosis, the diagnosis was established in childhood.


Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Mielofibrose Primária , Humanos , Receptores de Antígenos de Linfócitos T alfa-beta , Mielofibrose Primária/diagnóstico , Mielofibrose Primária/terapia , Transplante de Células-Tronco Hematopoéticas/métodos , Antígenos CD19 , Depleção Linfocítica/métodos , Condicionamento Pré-Transplante/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA